🇺🇸 Idarubicin(IDA) in United States
12 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 12
Most-reported reactions
- Acute Promyelocytic Leukaemia — 2 reports (16.67%)
- Central Nervous System Leukaemia — 2 reports (16.67%)
- Leukaemia Recurrent — 2 reports (16.67%)
- Acute Promyelocytic Leukaemia Differentiation Syndrome — 1 report (8.33%)
- Cognitive Disorder — 1 report (8.33%)
- Gait Disturbance — 1 report (8.33%)
- Hydrocephalus — 1 report (8.33%)
- Stem Cell Transplant — 1 report (8.33%)
- Visual Impairment — 1 report (8.33%)
Other Oncology approved in United States
Frequently asked questions
Is Idarubicin(IDA) approved in United States?
Idarubicin(IDA) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Idarubicin(IDA) in United States?
Chinese Academy of Medical Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.